Navigation Links
Drug Re-Sensitizes Breast Tumors to Treatment
Date:9/5/2008

Phase II study finds sorafenib helps reverse disease resistance to anti-hormonal therapy

FRIDAY, Sept. 5 (HealthDay News) -- The drug sorafenib may help "re-sensitize" certain breast cancer tumors to anti-hormonal drugs, Georgetown University Medical Center researchers say.

Women with estrogen-receptor or progesterone-receptor positive (ER or PR positive) metastatic breast cancers often take anti-hormonal medicines, such as aromatase inhibitors, to keep the cancer under control. Aromatase inhibitors lower the amount of estrogen in the body.

However, the tumor eventually becomes resistant to anti-hormonal drugs, and the cancer begins to grow.

"At first, the tumor's growth is halted, because the aromatase inhibitor is depriving the cancer of the estrogen it needs to grow. Eventually, though, the cancer will figure out another way to thrive in the absence of the estrogen," Dr. Claudine Isaacs, clinical director of the breast cancer program at Georgetown University Medical Center's Lombardi Comprehensive Cancer Center, said in a university news release.

Isaacs and her colleagues wanted to find out if a new approach can restore the effectiveness of anti-hormonal drugs against these tumors.

The phase II study included 27 postmenopausal women with metastatic breast cancer that had recurred or progressed while the women were taking the aromatase inhibitor anastrozole. Preliminary analysis of study data showed that 26 percent of the women showed a clinical benefit response while taking both sorafenib and anastrozole.

"Given what we know about the ineffectiveness of sorafenib alone in metastatic breast cancer, we believe the benefit that we're seeing may be attributable to the restoration of sensitivity to aromatase inhibitors," Isaacs said. "To manage breast cancer long-term, it's apparent that we may need to continually switch drugs to keep up with how a cancer evolves and evades each approach. In a sense, for each step back, we hope to take two steps forward."

The study was to be presented Sept. 5 at the 2008 ASCO Breast Cancer Symposium in Washington, D.C. Isaacs is part of the speaker's bureau for Pfizer Inc., which makes the aromatase inhibitor Exemestane.

More information

The U.S. National Cancer Institute has more about breast cancer treatment.



-- Robert Preidt



SOURCE: Georgetown University Medical Center, news release, Sept. 5, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Breast Cancer Drug Not Tied to Cognitive Decline: Study
2. Hospitals provide formula sample packs while medical organizations encourage breastfeeding
3. Komen Travels to Republican Convention to Raise Awareness of Breast Cancer Issues
4. Superbug breast infections controllable in nursing mothers, UT Southwestern researchers find
5. Komen Travels to Democratic Convention in Denver to Raise Awareness of Breast Cancer Issues
6. Taking Codeine While Breast-Feeding May Harm Infant
7. Breastfeeding, other factors may affect risk of breast cancer type
8. Zoft Breast Enhancement Gum Revolutionizes Breast Enhancement Industry
9. Risk of Breast Cancer Relapse Can Linger
10. Risk assessment plays key role in long-term treatment of breast cancer
11. MedexSupply Announces the Release of the ADC Limited Edition Pink Ribbon Stethoscope, With Proceeds Being Donated to Breast Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... and financial planning firm that serves residential and commercial clients in the greater ... drive to raise community support for the fight against cancer. , Founded by ...
(Date:8/18/2017)... ... 18, 2017 , ... With over 16,000 active patients, BodyLogicMD, ... therapy and integrative medicine, has become a frontrunner for people seeking help with ... andropause, thyroid disorder and adrenal insufficiencies. , Founded in 2003 by Patrick ...
(Date:8/18/2017)... ... August 18, 2017 , ... Inc. magazine has ranked American ... prestigious ranking of the nation's fastest-growing private companies. This marks the eighth time in ... 5000 ranking . This year’s ranking reflects ASH’s 76 percent overall revenue growth from ...
(Date:8/18/2017)... ... 2017 , ... “Dangerous Inheritance”: a mystery about saving the family farm. ... Southwest Nebraska where she was raised on a farm. As Diane wrote this ... but the friendships and mantra of ‘neighbors helping neighbors’ have always been a large ...
(Date:8/18/2017)... ... 18, 2017 , ... “Depressed: Super Heroes of the Bible”: a gripping ... stories and the relevance these tales may have on the reader’s life. “Depressed: Super ... special education teacher, Jessica spends much of her time enjoying nature and her family ...
Breaking Medicine News(10 mins):
(Date:8/3/2017)... Aug. 3, 2017  Opioid addiction and other drugs ... healthcare costs and threatening outcomes, were problems taken on ... IVD industry that support them, met this week. This ... said that drugs of abuse, procalcitonin and acute kidney ... the organization,s 69th meeting in San Diego, ...
(Date:8/2/2017)... and BENTON, Ky. , Aug. 2, 2017   Marshall ... to its environmental services (ES) team to proactively reduce the risk of hospital-acquired infections (HAIs). ... UV disinfection robot that uses UVC light energy to kill deadly pathogens such as ... Tru-D ... Tru-D in action ...
(Date:8/2/2017)... Aug. 2, 2017 CaryRx, a next-generation full-service pharmacy, ... service for patients in the Washington D.C. ... pharmacy by providing delivery of medications through the convenience of ... delivery or delivered within one hour to any location in ... to bring this invaluable service to Washington D.C. ...
Breaking Medicine Technology: